3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
25
Advanced Breast Cancer
2
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
ESR1 Gene Mutation
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Patients
1
Brain Neoplasms
1
Brain Diseases
1
Advanced ER+, HER2-Negative Breast Cancer
1
Interventions
Anastrozole
8
exemestane
7
Trastuzumab
7
Letrozole
7
palbociclib
6
Docetaxel
6
abemaciclib
5
Fulvestrant
5
ribociclib
4
pyrotinib
4
entinostat
4
Cyclophosphamide
4
Tamoxifen
3
Doxorubicin
3
pertuzumab
2
Sodium Chloride
2
Paclitaxel
2
Lapatinib
2
Gonadotropin-Releasing Hormone
2
Exercise
2
Everolimus
2
Epirubicin
2
Drug Evaluation
2
Capecitabine
2
Botulinum Toxins, Type A
2
Blood Specimen Collection
2
Aromatase Inhibitors
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Diseases
×
elacestrant
×
Breast
×
Clear all
NCT05386108
2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled